Eumedica Pharmaceuticals, a different partnership to the hospital environment, seeks to ensure the development and continuity of vital treatment in serious indications.

Due to the emergence of multi-resistant Gram-negative bacteria, Eumedica reintroduced in 2006 Negaban Temocillin in the UK market.